Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers

[1]  C. James,et al.  Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas , 2018, Clinical Cancer Research.

[2]  G. Pfeifer.  Defining Driver DNA Methylation Changes in Human Cancer , 2018, International journal of molecular sciences.

[3]  M. Mikuła,et al.  IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma , 2018, Journal of Cancer.

[4]  C. Perou,et al.  The association between copy number aberration, DNA methylation and gene expression in tumor samples , 2018, Nucleic acids research.

[5]  Pedro P. Rocha,et al.  Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. , 2017, Cell reports.

[6]  C. Marosi,et al.  Correlation of immune phenotype with IDH mutation in diffuse glioma , 2017, Neuro-oncology.

[7]  A. M. Houghton,et al.  Mutant IDH1 regulates the tumor-associated immune system in gliomas , 2017, Genes & development.

[8]  J. Costello,et al.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.

[9]  Peter W. Laird,et al.  Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes , 2016, Nucleic acids research.

[10]  D. Kondziolka,et al.  Mutant IDH1 and thrombosis in gliomas , 2016, Acta Neuropathologica.

[11]  A. Jeltsch,et al.  Allosteric control of mammalian DNA methyltransferases – a new regulatory paradigm , 2016, Nucleic acids research.

[12]  Gary D. Bader,et al.  AutoAnnotate: A Cytoscape app for summarizing networks with semantic annotations , 2016, F1000Research.

[13]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[14]  J. Engh,et al.  IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. , 2016, Neuro-oncology.

[15]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[16]  [World Health Organization classification of tumours of the central nervous system: a summary]. , 2016, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[17]  Gianluca Bontempi,et al.  TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. , 2016, F1000Research.

[18]  Gwendolyn M. Jang,et al.  Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. , 2015, Cell host & microbe.

[19]  Darrell,et al.  Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. , 2015, The oncologist.

[20]  K. Ross,et al.  Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.

[21]  D. Brat,et al.  PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma , 2013, Brain pathology.

[22]  M. Ross,et al.  Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 , 2013, Nature Communications.

[23]  C. Horbinski.  What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.

[24]  Derek Y. Chiang,et al.  Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.

[25]  G. Reifenberger,et al.  IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics , 2012, Nature.

[26]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[27]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[28]  Y. Benjamini,et al.  Summarizing and correcting the GC content bias in high-throughput sequencing , 2012, Nucleic acids research.

[29]  Zhujun Wang,et al.  Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. , 2012, American journal of blood research.

[30]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[31]  K. Gunderson,et al.  High density DNA methylation array with single CpG site resolution. , 2011, Genomics.

[32]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[33]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[34]  T. Shibata,et al.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. , 2011, The American journal of pathology.

[35]  Reid F. Thompson,et al.  Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis , 2011, PLoS genetics.

[36]  Hai Yan,et al.  2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations , 2011, PloS one.

[37]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[38]  Gary D Bader,et al.  Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.

[39]  R. McLendon,et al.  IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. , 2010, Biochemical and biophysical research communications.

[40]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[41]  Jih-Luh Tang,et al.  Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. , 2010, Blood.

[42]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[43]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[44]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[45]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[46]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[47]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[48]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[49]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[50]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[51]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[52]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[53]  L. Herzenberg,et al.  DNA methylation prevents the amplification of TROP1, a tumor-associated cell surface antigen gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.